Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
1(13%)
Results Posted
0%(0 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
5
63%
Ph phase_2
2
25%
Ph phase_3
1
13%

Phase Distribution

5

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (62.5%)
Phase 22 (25.0%)
Phase 31 (12.5%)

Trials by Status

completed563%
recruiting113%
terminated225%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_3

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

NCT07168161
completedphase_1

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

NCT05197842
terminatedphase_2

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

NCT04449588
terminatedphase_1

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

NCT05075304
completedphase_1

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05103423
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07168161Phase 3

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

Recruiting
NCT05197842Phase 1

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Completed
NCT04449588Phase 2

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

Terminated
NCT05075304Phase 1

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

Terminated
NCT05103423Phase 1

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed
NCT05093855Phase 2

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed
NCT05361005Phase 1

Tolerability and Safety of BDB-001 Injection in Healthy Subjects

Completed
NCT05360927Phase 1

Safety and Tolerability of BDB-001 Injection in Healthy Subjects

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8